| The availability, pricing and affordability of three essential asthma medicines in 52 low-and middle-income countries ZUD Babar, C Lessing, C Mace, K Bissell Pharmacoeconomics 31, 1063-1082, 2013 | 101 | 2013 |
| The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand C Lessing, T Ashton, P Davis Journal of primary health care 7 (2), 94-101, 2015 | 15 | 2015 |
| The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand C Lessing, T Ashton, P Davis Applied health economics and health policy 12, 537-546, 2014 | 14 | 2014 |
| Exploring pharmacists' opinions regarding PHARMAC's interventions in promoting brand changes ZU Babar, A Polwin, SW Kan, N Amerasinghe, S McCarthy, F Rasheed, ... Research in Social and Administrative Pharmacy 11 (1), 96-110, 2015 | 10 | 2015 |
| Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment C Lessing, T Ashton, P Davis Administration and Policy in Mental Health and Mental Health Services …, 2015 | 9 | 2015 |
| Decision-making on listing new medicines for public funding in New Zealand: the case of ‘new’type 2 diabetes medications F Sarkisova, C Lessing, C Stretton Journal of Primary Health Care 14 (1), 13-20, 2022 | 5 | 2022 |
| New Zealand patients’ understanding of brand substitution and opinions on copayment options for choice of medicine brand C Lessing, T Ashton, P Davis Australian Health Review 40 (3), 345-350, 2015 | 5 | 2015 |
| An evaluation of health service impacts consequent to switching from brand to generic venlafaxine in New Zealand under conditions of price neutrality C Lessing, T Ashton, P Davis Value in Health 18 (5), 646-654, 2015 | 5 | 2015 |
| Pharmaceutical pricing policies in the Gulf Countries’ Council (GCC) and the United Arab Emirates (UAE) RSI Hasan, C Lessing Pharmaceutical prices in the 21st century, 297-307, 2014 | 4 | 2014 |
| Evaluating general practitioners' opinions on issues concerning access to medicines in New Zealand ZUD Babar, C Lessing, J Stewart, J Sheridan Journal of Pharmaceutical Health Services Research 6 (3), 145-154, 2015 | 1 | 2015 |
| Reference pricing and health outcomes: Evaluating the impact of generic substitution in New Zealand C Lessing PhD Thesis-University of Auckland, 2015 | 1 | 2015 |
| Public Participation in PHARMAC: The Perspective of Consumer Groups C Lessing University of Auckland, 2009 | 1 | 2009 |
| How well does social work education in Aotearoa New Zealand prepare social workers to work with people claiming welfare benefits and what could be done better? A Russell, C Lessing Aotearoa New Zealand Social Work 36 (1), 60–74-60–74, 2024 | | 2024 |
| The Influence of Stigma on Provision of HIV Pharmaceutical Care in New Zealand C Lessing AUT University, 2018 | | 2018 |
| Switch to generic lamotrigine a good move in NZ? C Lessing PharmacoEconomics & Outcomes News 708, 8-2, 2014 | | 2014 |
| CORRESPONDENCE TO: Charon Lessing C Lessing, T Ashton, PB Davis | | |
